
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp is positioned for robust growth, particularly with its MACI product, which is projected to achieve a year-over-year revenue increase of approximately 21.2% in FY26, driven by a combination of volume growth and annual average selling price (ASP) increases. The company anticipates a significant rise in quarterly revenue, with 4Q expectations reaching $84.8 million, reflecting a 26% quarter-over-quarter growth. Additionally, the sustained growth in MACI's revenues, supported by a compound annual growth rate (CAGR) of 14.8% in volume alongside an annual ASP growth of 300 to 500 basis points, lays a solid foundation for long-term financial performance.
Bears say
Vericel Corp has revised its revenue expectations for its MACI product downward by approximately 200 basis points for fiscal years 2026 and 2027, indicating potential challenges in meeting previous forecasts. Key financial risks include lower than anticipated uptake of MACI Arthro, slower sales growth in the burn care segment, and the possibility of operational disruptions due to sales force expansion efforts. Additionally, uncertainties surrounding physician adoption rates for MACI, inconsistent usage of Epicel among burn patients, and delays in NexoBrid's approval contribute to a pessimistic outlook, with potential repercussions on share valuation if quarterly top-line expectations are missed.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares